We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

STANDARD DIAGNOSTICS INC.

Standard Diagnostics develops rapid diagnostic tests that make it possible to diagnose various diseases at an earlier... read more Featured Products: More products

Download Mobile App




Malaria Parasite Evades Rapid Test Detection in Children

By LabMedica International staff writers
Posted on 30 Nov 2016
Rapid diagnostic tests account for more than 70% of diagnostic testing for malaria in Africa and most rapid test diagnostics rely on the detection an antigen specific to Plasmodium falciparum malaria.

The Democratic Republic of the Congo (DRC) has one of the highest rates of people living with malaria. More...
Most rapid test diagnostics (RDT) rely on the detection of histidine-rich protein 2 (HRP2), an antigen specific to P. falciparum malaria. However, one of every 15 children infected with P. falciparum malaria parasites in the DRC is infected by a pfhrp2-deleted mutant, producing a false-negative result when an RDT is used.

An international team of scientists led by those at University of North Carolina Health Care System (Chapel Hill, NC, USA) collected samples from children under five years of age as part of the 2013- 2014 DRC Demographic and Health Survey. The majority of children were asymptomatic at the time of sample collection. Heel- or finger-prick blood from each participant was analyzed by light microscopy for parasites, applied to an RDT targeting the P. falciparum HRP2 antigen.

The samples were applied to an RDT targeting the P. falciparum HRP2 antigen (SD BIOLINE Malaria Ag P.f., Standard Diagnostics, Gyeonggi-do, Republic of Korea), and used to prepare dried blood spots (DBS). Three diagnostic methods were performed for each child: RDT, microscopy, and polymerase chain reaction (PCR). The real-time PCR assay with a limit of detection of 100 parasites/μL was employed to identify P. falciparum infection by amplifying a region of the single-copy pfldh gene.

The team focused on 783 samples with opposing rapid test diagnostic test and polymerase chain reaction (PCR) results. PCR testing showed positive results for malaria where rapid diagnostic testing did not. They identified 149 pfhrp2-deleted parasites, representing 6.4% of all P. falciparum infections country-wide among the 2,752 children diagnosed with P. falciparum infection by real-time PCR and 19.0 % of the 783 RDT-/PCR+ parasites tested.

Jonathan Parr, MD. MPH. the study's lead author, said, “This is the first nationwide study to demonstrate the presence and estimate the prevalence of malaria caused by pfhrp2-deleted P. falciparum in asymptomatic children. Because most rapid diagnostic tests in the DRC are HRP2-based, they will fail to detect these parasites. Their spread would represent a serious threat to malaria elimination efforts.” The study was published on November 14, 2016, in the Journal of Infectious Diseases.

Related Links:
University of North Carolina Health Care System
Standard Diagnostics

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.